MCS 4: Colposcopy and CIN during pregnancy

Chairs: Dr Efraim Siegler, Israel & Dr Mihaela Grigore, Romania

• HPV and complications in pregnancy: Dr Anita Mitra, UK
• Vertical transmission of HPV during pregnancy – what do we know?: Dr Mihaela Grigore, Romania
• The difficulty of cervical cancer prevention by pap and colposcopy during pregnancy: Dr Christine Bergeron, France
• The outcome of CIN 2-3 in pregnancy?  The best way of delivery: Dr Zvi Vaknin, Israel
• Should CIN 2-3 be treated in pregnancy?: Dr Efraim Siegler, Israel
• Q&A session

Break

MCS 6: Special cases in pathology, colposcopy, and treatment

Chairs: Dr Olaf Reich, Austria & Dr Laura Kotaniemi-Talonen, Finland

• Immune microenvironment in SIL of the cervix: Dr Ruud Bekkers, The Netherlands
• HPV-independent cervical cancer and precancer: Dr Miriam Elfström, Sweden
• New concepts in excisional treatment of HSIL and AIS: Dr Olaf Reich, Austria
• Challenges on the way of elImination of cervical cancer in Eastern Europa: Dr Natalia Volodko, Ukraine
• Q&A session

Break

MSS 4: Prophylactic HPV-vaccines

Chairs: Dr Ruud Bekkers, The Netherlands & Dr Ilkka Kalliala, Finland

• HPV type replacement after prophylactic vaccination: Dr Penelope Gray, Finland
• HPV vaccines, CIN and preterm birth: Dr Ilkka Kalliala, Finland
• HPV vaccination for high-risk adult women, including after CIN treatment: Dr Heleen van Beekhuizen, The Netherlands
• Screening after HPV vaccination: Dr Peter Sasieni, UK
• Q&A session

Break

Free Communications 5

Chairs : Dr Tamar Alibegashvili, Dr Julia heikkinen

• Plisko (abstract 10) Association between high-risk HPV E6/E7 expression, sexually transmitted infections, and urogenital mycoplasmas in women with cervical intraepithelial neoplasia
  STDs and HIV
• Lokshina (abstract 8) Efficacy of artificial intelligence in diagnosing cervical precancer
  Colposcopy
• Krog (abstract 17) Evaluation of training in colposcopy and loop electrosurgical excision procedure among danish residents in obstetrics and gynecology: a questionnaire study
  Colposcopy
• Tidy (abstract 42) Real world data shows electrical impedance spectroscopy increases detection of HG-CIN in multiple healthcare settings.
  Colposcopy
• Dina Overgaard (abstract 34) Can human papillomavirus vaccination reduce the risk of recurrence in women undergoing excisional treatment for cervical intraepithelial neoplasia? A systematic review and meta-analysis
  HPV vaccination
• Reuschenbach (abstract 11) Real world evidence of 4vhpv/9vhpv vaccine effectiveness and impact in high-risk populations
  HPV Vaccination

Colposcopy in practice – Cases 2

Chairs: Dr Tamar Alibegashvili, Georgia & Dr Annu Heinonen, Finland

• Dr Ameli Trope
• Dr Irina Jermakova
• Dr Miriam Elfström
• Dr Tamar Alibegashvili
• Dr Annu Heinonen

Break

MCS 5: Keynote 2: future of screening and colposcopy

Chairs: Dr Maggie Cruickshank, UK & Dr Xavier Carcopino, France

• Keynote Lecture 2a: The future of cervical cancer screening: Dr Mari Nygård, Norway
• Keynote Lecture 2b: Triage and prognostic markers in cervical cancer screening: Dr Cara Martin, Ireland
• Keynote Lecture 2c: QA of colposcopy for HPV-based screening programmes and HPV-vaccinated populations: Mr Simon Leeson, UK
• Q&A session

Break

MCS 7: Guidelines and QI for colposcopy in Europe

Chairs: Mr Simon Leeson, UK & Mr Charles Redman, UK

• European guidelines, where we are, the importance of consensus and linkage to QIs: Dr Maggie Cruickshank, UK
• Influence of international guidelines: Dr Jean-Luc Mergui, France
• Quality Indicators: relevant and reproducible?: Mr Simon Leeson, UK
• Implementing international guidelines locally. The value of incorporation of international into national guidelines: Dr Maciej Mazurec, Poland
• Q&A session

Break

Free Communications 4

Chairs : Dr Christine Bergeron, Dr Karoliina Aro

• Omar (abstract 7) Cumulative two-year risk of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and contributing factor after low-grade cytology
  Colposcopy
• Bergqvist (abstract 4) Added value of electrical impedance spectroscopy in adjunction of colposcopy: a prospective cohort study
  Colposcopy
• McGee (abstract 38) Increasing Colposcopy Workload in Scotland: Identifying Capacity Following Primary HPV Screening
  Colposcopy
• Arbyn (abstract 19) Clinical validation of portable colposcopy devices using the VALcolp protocol
  Colposcopy
• Lokshina (abstract 9) Efficacy of truscreen and EVA visualcheck AI in diagnosing cervical intraepithelial neoplasia: a comparative study
  Colposcopy
• Hammer (abstract 15) Extent of latent HPV infections in older Danish women with a previous history of cervical dysplasia
  Colposcopy

Break

MSS 5: The male factor in HPV transmission and vaccination programmes

Chairs: Dr Kristina Elfgren, Sweden & Dr Arne Wikström, Sweden

HPV infection among men — a clinical perspective : Dr Arne Wikstrom, Sweden

Transmission — only within heterosexual couples? : Dr Kristina Elfgren, Sweden

HPV vaccination in males and heterosexual couples : Dr Matti Lehtinen, Finland

Free Communications 3

Chairs: Mr Simon Leeson, Dr Illka Kalliala

• Delli Carpini (abstract 6) Monitoring the activities of Italian colposcopy clinics before and during the Covid-19 pandemic
  Management of SIL/ AIS (CIN and CGIN) (follow-up, treatment)
• Kiviharju (abstract 33) Overtreatment rate after immediate local excision of suspected cervical intraepithelial neoplasia: a prospective cohort study
  Management of SIL/ AIS (CIN and CGIN) (follow-up, treatment)
• Hammer (abstract 14) P16/Ki67 dual stain cytology for detection of cervical precancer in women with a transformation zone type 3
  Management of SIL/ AIS (CIN and CGIN) (follow-up, treatment)
• Morello (abstract 21) Predictors factors of the absence of high-grade intraepithelial lesion in excisional therapy specimen
  Management of SIL/ AIS (CIN and CGIN) (follow-up, treatment)
• Lycke (abstract 35) Long-term risk of cervical cancer in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2 – a population-based cohort study
  Management of SIL/ AIS (CIN and CGIN) (follow-up, treatment)
• Miranda (abstract 36) Positive margins for high-grade intraepithelial lesion after conization – a five-year retrospective study
  Management of SIL/ AIS (CIN and CGIN) (follow-up, treatment)
• Kylebäck (abstract 37) Expectancy as alternative to treatment for cervical intraepithelial neoplasia grade 2 (cin2) in women aged 25-30 years
  Management of SIL/ AIS (CIN and CGIN) (follow-up, treatment)

Break

Cervical Cancer Screening Audit and Medico-legal issues

Chairs: Mr Charles Redman, UK & Dr Volkmar Küppers, Germany

• The potential of national cancer screening audit: Dr Peter Sasieni, UK
• Swedish cancer screening audits: Dr Miriam Elfström, Sweden
• English cancer screening audits: Dr Phillippa Pearman, UK
• Disclosure of cervical cancer audit findings: Dr Theresa Freeman-Wang, UK
• Q&A session

Break

Cervical cancer prevention in underscreened countries

Chairs: Dr Robert Jach, Poland, & Dr Jana Žodžika, Latvia

• Prevention of cervical cancer in Serbia – opportunities and limitations: Dr Vesna Kesic, Serbia
• How can we improve adherence to the screening?: Dr Michaela Grigore, Romania
• Challenges of cervical cancer screening programme in Lithuania: Dr Kristina Jariene, Lithuania
• HPV test as a primary screening tool in all resource settings (The Balkan Perspective): Dr Goran Dimitrov, Northern Macedonia
• Is organized population-based model the universal strategy for all underscreened populations? – hybrid screening strategy as a chance for Poland: Dr Martyna Trzeszcz, Poland
• Q&A session

Break

EFC General Assembly

MCS 8: Improving selection of new technologies in colposcopy

Chairs: Mr Charles Redman, UK & Dr Tamar Alibegashvili, Georgia

• Risk-based management focused on risk stratification – a multi parameter approach: Dr Martyna Trzeszcz, Poland
• Improving diagnosis with Zedscan: Dr John Tidy, UK
• Improving diagnosis with Dysis: Dr Jacqueline Louwers, The Netherlands
• The potential role of AI in the Polish context: Dr Robert Jach, Poland
• Q&A session

Break

MCS 9: Media coverage and social media

Chairs: Dr Ameli Trope, Norway & Dr Grainne Flannelly, Ireland

• Setting the scene – The role of media and social media in establishing trust in cervical cancer prevention programmes: Dr Grainne Flannelly, Ireland
• What women know about HPV and lessons learned about how this might affect uptake of a HPV based cervical screening programme: Dr Mairead O’Connor, Ireland
• The use of social media campaigns to drive uptake of cervical screening in the UK: Mrs Samantha Dixon, UK
• Risk and benefits of LLETZ – what women really think and what lessons can we learn about influencing behaviour and establishing trust: Dr Ameli Trope, Norway
• Using social media campaigns to tackle disinformation about HPV vaccination – a strategy that worked: Ms Muiriosa Ryan, Ireland

MSS 6: Impact of Covid-19 on cervical screening, prevention and prognosis

Chairs: Mr Simon Leeson, UK & Dr Xavier Carcopino, France

• Impact of Covid-19 outbreak on cervical cancer screening throughout Europe: Dr Xavier Carcopino, France
• BSCCP colposcopy training and the exit exam and what was done during Covid: Dr Deirdre Lyons, UK
• Early lessons from the coronavirus pandemic for the cervical screening programme in Wales: Mr Simon Leeson, UK
• Experience from the Netherlands with Covid and self-sampling: Dr Anne-Marie van Haaften-de-Jong, The Netherlands
• Q&A session

Break

Round Table on The future roles for the EFC

Chairs: Dr Jens Quaas, Germany; Dr Maggiorino Barbero, Italy

Introduction : Mr Charles Redman, UK

What are the future priorities for the EFC and how should the EFC achieve these: Dr Robert Jach, Poland; Dr Volkmar Küppers, Germany; Dr Amelia Pedro, Portugal & Dr Ilkka Kalliala, Finland

Conclusion : Dr Pekka Nieminen, Finland & Dr Margaret Cruickshank, UK